Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Century Therapeutics, with four buys, two holds and one sell among seven firms. The average 12-month price target is $4.75, compared with the stock’s recent price of $2.12.
• Institutional ownership increased as several major investors raised their stakes, including AQR Capital Management, Bank of America and Acadian Asset Management. Hedge funds and other institutions collectively own 50.2% of the company.
• Century Therapeutics reported a quarterly loss of $0.17 per share, missing the $0.11 loss analysts expected. The clinical-stage biotech is developing iPSC-based “off-the-shelf” cell therapies for cancer.

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned a consensus recommendation of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $4.75.

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Mizuho initiated coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 price target for the company. Finally, Wall Street Zen lowered shares of Century Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC raised its holdings in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after purchasing an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock valued at $86,000 after buying an additional 38,052 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock valued at $133,000 after buying an additional 142,953 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $25,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Stock Performance

Century Therapeutics stock traded up $0.04 during trading hours on Monday, hitting $2.12. The company had a trading volume of 119,647 shares, compared to its average volume of 1,389,911. The firm has a market cap of $382.96 million, a P/E ratio of -2.27 and a beta of 1.57. Century Therapeutics has a 1 year low of $0.44 and a 1 year high of $3.04. The company has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $2.21.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.06). As a group, equities research analysts anticipate that Century Therapeutics will post -0.47 EPS for the current year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source